Return to Press Releases
06/05/2018
FamilyWize Partners with Personalized Medicine Company MedTek21
BETHLEHEM, PA—June 5, 2018 — FamilyWize announced today a partnership that will give the public greater
access to personalized medicine, helping patients better understand how their unique genetic profiles can
influence how they metabolize certain medications. As part of this effort, FamilyWize has partnered with
MedTek21, a software-based platform that helps both patients and their care providers identify hidden medication
risks and optimize prescribed medications for maximum efficacy.
FamilyWize and MedTek21 can help patients by offering access to MedTek21 Direct, an easy-to-use personalized
medication management program. This program can help patients learn if they have been prescribed a medication
that might be impacted by their unique metabolic profile. MedTek21’s software and mobile application
continuously keep patients and their physicians up to date and proactively flag any new potential issues in real
time. Should a prescribed medication be indicated to not improve the patient’s health, this means money is being
spent on a potentially ineffective prescription with each monthly refill.
To learn more, patients can visit https://familywize.org/commercial-partners/medtek21. Within a few days of
submitting basic medication information to MedTek21, the patient and their care provider will receive actionable
data and clear summary reports highlighting potential issues based on currently prescribed medications.
MedTek21 also provides the latest information about the patient’s potential reactions to an expanding list of over
250 common medication compounds and incorporates the latest in FDA prescribing guidelines and clinical
research.
The partnership potentially enables consumers to experience positive results both physically and financially. The
patient’s care providers can easily interpret MedTek21 Direct results to increase the efficiency of drug therapy
through adjustments in the medication or medication dosages. In addition, patients can save significantly on the
safest and most effective medications through FamilyWize and avoid the need to waste time and money on
potentially ineffective medications.
“The prescribing of medications which are metabolized abnormally by certain patients is a growing problem, and
these patients are suffering physically and financially as a result,” said Joseph Sanginiti, President and Chief
Executive Officer of FamilyWize. “As advocates for the physical and financial well-being of all Americans,
FamilyWize is addressing the issue head-on. Our partnership with MedTek21 will offer patients easy access to
details on their unique genetic profiles and enable physicians to more accurately determine affordable treatment
options. Together we will expand awareness of MedTek21 Direct and the positive impact of personalized medicine
on savings and overall health.”
“We’re very pleased to announce this partnership with FamilyWize,” said Steve Salvitti, CEO of MedTek21.
“Millions of FamilyWize users who have benefited from lower cost medications will now also have access to
MedTek21’s mobile application, risk assessment tools, proactive recommendations, and clinical support team to
analyze and remediate drug-to-gene risks. FamilyWize has a proud history of innovations that empower patients to
play a role in the management of both their care and their care costs, and this partnership will truly help patients
to get the best medication, at the optimal dose, and at the best price.”
Download a PDF of this press release